Title |
Metformin monotherapy for type 2 diabetes mellitus
|
---|---|
Published by |
John Wiley & Sons, Ltd, July 2005
|
DOI | 10.1002/14651858.cd002966.pub3 |
Pubmed ID | |
Authors |
Saenz, Antonio, Fernandez-Esteban, Inmaculada, Mataix, Angel, Ausejo Segura, Monica, Roqué i Figuls, Marta, Moher, David |
Abstract |
Metformin is an anti-hyperglycaemic agent used for the treatment of type 2 diabetes mellitus. Type 2 diabetes may present long-term complications: micro- (retinopathy, nephropathy and neuropathy) and macrovascular (stroke, myocardial infarction and peripheral vascular disease). Two meta-analyses have been published before, although only secondary outcomes were assessed. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 14% |
Unknown | 6 | 86% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 7 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 243 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 3 | 1% |
Brazil | 3 | 1% |
Italy | 2 | <1% |
United States | 2 | <1% |
Denmark | 1 | <1% |
Ireland | 1 | <1% |
Unknown | 231 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 37 | 15% |
Student > Bachelor | 36 | 15% |
Researcher | 29 | 12% |
Student > Ph. D. Student | 24 | 10% |
Other | 19 | 8% |
Other | 47 | 19% |
Unknown | 51 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 119 | 49% |
Agricultural and Biological Sciences | 18 | 7% |
Nursing and Health Professions | 13 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 4% |
Biochemistry, Genetics and Molecular Biology | 6 | 2% |
Other | 17 | 7% |
Unknown | 60 | 25% |